Literature DB >> 11180568

Theory versus practice: a review of 'willingness-to-pay' in health and health care.

J A Olsen1, R D Smith.   

Abstract

This paper is based upon an extensive review of 71 willingness-to-pay (WTP) surveys of health and health care published in English during the period 1985--1998. The aim of the paper is to outline the arguments advanced for the superiority of WTP over quality-adjusted-life-years (QALYs) as a measure of benefit of health care programmes, and to review how empirical WTP studies adhere to their implications. An important argument is that WTP enables a more comprehensive valuation of benefits than QALYs. Our main focus is therefore to provide a careful review of the scenario descriptions used in the surveys, according to which types of benefits are being valued, and how comprehensively the descriptions are presented. Furthermore, the 'cost-benefit argument', that WTP can assist in improving social efficiency, is discussed before we inquire into the extent to which the studies actually compare WTP with social costs. Copyright 2001 John Wiley & Sons, Ltd.

Mesh:

Year:  2001        PMID: 11180568     DOI: 10.1002/1099-1050(200101)10:1<39::aid-hec563>3.0.co;2-e

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  82 in total

1.  The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.

Authors:  Grace Wu; Krista L Lanctôt; Nathan Herrmann; Shehnaz Moosa; Paul I Oh
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  The measurement of contingent valuation for health economics.

Authors:  Ahmed M Bayoumi
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Willingness to pay for dental fear treatment. Is supplying dental fear treatment socially beneficial?

Authors:  Bente Halvorsen; Tiril Willumsen
Journal:  Eur J Health Econ       Date:  2004-12

Review 4.  Economic evaluations of childhood influenza vaccination: a critical review.

Authors:  Anthony T Newall; Mark Jit; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

Review 5.  Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.

Authors:  R S Taylor; M F Drummond; G Salkeld; S D Sullivan
Journal:  BMJ       Date:  2004-10-23

Review 6.  Willingness to pay for a QALY: theoretical and methodological issues.

Authors:  Dorte Gyrd-Hansen
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Willingness-to-pay and demand curves: a comparison of results obtained using different elicitation formats.

Authors:  David K Whynes; Emma J Frew; Jane L Wolstenholme
Journal:  Int J Health Care Finance Econ       Date:  2005-12

Review 8.  A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?

Authors:  Tracey H Sach; Richard D Smith; David K Whynes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

9.  Economic analysis of an internet-based depression prevention intervention.

Authors:  Alexander Ruby; Monika Marko-Holguin; Joshua Fogel; Benjamin W Van Voorhees
Journal:  J Ment Health Policy Econ       Date:  2013-09

10.  Valuing benefits to inform a clinical trial in pharmacy : do differences in utility measures at baseline affect the effectiveness of the intervention?

Authors:  Michela Tinelli; Mandy Ryan; Christine Bond; Anthony Scott
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.